Dr. Reddy’s Delivers Solid First-Half Results; Acquisitions and ...
8 hours ago · We believe Dr. Reddy’s is in good financial health. At the end of fiscal 2023, the company had roughly INR 5.8 billion in cash and equivalents and a total debt balance of less than INR 9.0 billion.
India's Dr Reddy's Q2 profit drops on acquisition cost, impairment ...
17 hours ago · The company also reported an impairment charge due to supply chain constraints in U.S. affecting a particular generic medical product. Reddy's reported a 9.5% fall in its consolidated net profit ...
Healthcare major Dr Reddy's Q2 net profit falls, revenue
17 hours ago · Dr Reddy's posted a consolidated net profit of ₹1,255 crore for Q2 FY25, down 15% from last year, while revenue rose 17% to ₹8,016 crore. Healthcare major Dr Reddy's Laboratories reported a 15% decline in its consolidated net profit, totalling ₹1,255 crore for the second quarter of FY25, compared to ₹1,480 crore in the same period last ...
Dr Reddy’s Q2 profits decline 9%, revenue grows 17%
16 hours ago · Dr Reddy’s reports 9% drop in Q2 profit despite 17% revenue growth. Pharma major Dr Reddy’s Laboratories’ consolidated net profit declined 9 per cent to ₹1,341 crore in the second quarter ...
Dr Reddy's Laboratories Q2 Results: Key Metrics - Mint
17 hours ago · Dr Reddy's Laboratories Q2 Results: Dr Reddy's Laboratories announced its July-September quarter results for fiscal 2024-25 (Q2FY25) on Tuesday, November 5, reporting a drop of 9.5 per cent in ...
Dr. Reddy’s to expand GLP-1 portfolio with focus on obesity and ...
13 hours ago · Dr Reddy’s consolidated net profit dropped 9.5% to ₹1,342 crore in the second quarter of FY25. Image: Pixabay Mumbai: Dr. Reddy’s Laboratories Ltd aims to have about 15 GLP-1 drugs, used to ...
Dr. Reddy’s Q2 & H1FY25 Financial Results - Morningstar
1 day ago · About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in ...
Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call …
Follow. Play Earnings Call. Dr. Reddy's Laboratories Limited (NYSE:RDY) Q2 2025 Earnings Conference Call November 5, 2024 9:00 AM ET. Company Participants. Richa Periwal - Head of Investor ...
Dr. Reddy’s Laboratories – Good Health Can’t Wait
Sep 30, 2024 · Dr. Reddy's Leads Indian Pharma As First Member Of DJSI World Index, Entering 2024 On Strong Footing. Dr. Reddy’s Laboratories, a leading multinational pharmaceutical company based in India and overseas, committed to providing affordable and innovative medicines for healthier lives.
India's Dr Reddy's tops Q2 profit view on strong US demand
Oct 27, 2023 · India's Dr Reddy's Laboratories reported a bigger-than-expected rise in second-quarter profit on Friday, boosted by strong U.S. sales of its generic version of popular cancer drug Revlimid.